ICLR's Quality Score rose 1 point on Tue, Nov 10, to 14. Trading was quieter than usual (2 chart checks started).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 17% on Oct 28, and still 13% over its Oct 27 close.
| Since its 2024 high | Down 40% |
| Latest filing | 6-K, Oct 27 |
After its last 4 reports it closed +9.1% on average, higher 3 of 4 times.
Above Averagefor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. ICLR scores 14 today, against a median of 10 over its last 20 recorded sessions.
ICLR is #30 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 30 |
Share count against a year before: ICLR -0.6%, IQV -3.2%, CRL -2.9%, MEDP -0.7%.
Expected to report Wed Feb 17, after the close (in 99 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
ICLR's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
| Measure | Figure |
|---|---|
| Revenue | $8.1B to $8.2B |
Sales grew 2.1% a year over 3 years, fiscal 2022 to 2025.
Its share count fell 1.4% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 27, 2026 | +8.9% | +17.0% | +11.4% |
| Jul 29, 2026 | -7.0% | -7.1% | -8.2% |
| Jun 23, 2026 | +3.6% | +10.9% | +21.8% |
Sales grew every year from 2021 to 2025, to $8.3B. It made a profit in each of the five years.
RSI 63.7, MACD above signal, above both averages. Not scored.
10 insiders sold $6.2M across 58 filings in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
“When competing for large development programs, ICON competes primarily with IQVIA, PAREXEL, the PPD clinical research services brand of Thermo Fisher Scientific Inc., Fortrea and Syneos Health.”
ICLR scores 14 today, which Breakaway calls Above Average. It is #30 of 281 in Biotech by Quality Score, with 7 of 14 chart checks firing. Up 17% on Oct 28, and still 13% over its Oct 27 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ICLR scores 14 today, which Breakaway calls Above Average (11 to 14). That is #30 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ICLR's 14.
10 insiders sold $6.2M across 58 filings in the last 6 months. No open-market buys on record. The newest is Ciaran Murray, Director, who sold $710K on Nov 2. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.